Who are MT-7117's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): AZD0901, MT-7117 high dose, MT-7117 low dose.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mt-7117.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

MT-7117 — Competitive Intelligence Brief

MT-7117 (MT-7117) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Soluble guanylate cyclase (sGC) activator. Area: Cardiovascular.

phase 3 Soluble guanylate cyclase (sGC) activator Soluble guanylate cyclase (sGC) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

MT-7117 (MT-7117) — Tanabe Pharma America, Inc.. MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MT-7117 TARGET	MT-7117	Tanabe Pharma America, Inc.	phase 3	Soluble guanylate cyclase (sGC) activator	Soluble guanylate cyclase (sGC)
AZD0901	AZD0901	AstraZeneca	phase 3	Soluble guanylate cyclase (sGC) activator	Soluble guanylate cyclase (sGC)
MT-7117 high dose	MT-7117 high dose	Tanabe Pharma America, Inc.	phase 3	Soluble guanylate cyclase (sGC) activator	Soluble guanylate cyclase (sGC)
MT-7117 low dose	MT-7117 low dose	Tanabe Pharma America, Inc.	phase 3	Soluble guanylate cyclase (sGC) activator	Soluble guanylate cyclase (sGC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Soluble guanylate cyclase (sGC) activator class)

Tanabe Pharma America, Inc. · 3 drugs in this class
AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MT-7117 — Competitive Intelligence Brief. https://druglandscape.com/ci/mt-7117. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab